Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies

 9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...

Read more →

Access to cancer medicines in the UK

1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...

Read more →

Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping

3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...

Read more →

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...

Read more →

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...

Read more →

Voclosporin with mycophenolate mofetil for treating lupus nephritis

3 May 2023 - NICE has issued evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in ...

Read more →

Ripretinib for treating advanced gastro-intestinal stromal tumour after three or more treatments

3 May 2023 - NICE has issued evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after ...

Read more →

Prioritising patients in negotiations over drug pricing

14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...

Read more →

NICE collaborates with international partner agencies to streamline the confidential marking process

24 April 2023 - NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and ...

Read more →

Tezepelumab for the treatment of patients with severe asthma

20 April 2023 - NICE has published evidence based recommendations on tezepelumab (Tezspire) for the treatment of patients 12 years ...

Read more →

Daratumumab in combination with bortezomib and dexamethasone for the treatment of patients with previously treated multiple myeloma

17 April 2023 - NICE has published final draft guidance on the use of daratumumab in combination with bortezomib and ...

Read more →

‘A global outlier’: how drug firms are fighting back against UK tax increases

13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...

Read more →

How ‘surrogate outcomes’ influence long-term health outcomes

13 April 2023 - NICE working with international organisations to develop guidance. ...

Read more →

Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement

11 April 2023 - The aims of this study were to review the current interactions within and across regulatory and HTA ...

Read more →

HTA barriers for conditional approval drugs

12 April 2023 - The objective of this study is to assess whether conditionally approved drugs face higher probabilities of HTA ...

Read more →